Dupilumab Skin Barrier Function Study in Atopic Dermatitis
Completed · Phase 4 · NCT04447417
Conditions: Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $36,944
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 52
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab SAR231893 (drug)
- Dates
- Started 2020-07-16; completion 2021-06-17
- Results posted
- Yes
Primary Objective: \- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in pre-defined lesional skin in participants with moderate to severe atopic dermatitis (AD) treated with dupilumab. Secondary Objectives: * Evaluate changes in skin barrier function with TEWL assessed after STS in pre-defined lesional and non-lesional skin in participants with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers. * Evaluate time course of skin barrier function with TEWL assessed before and after STS in pre-defined lesional and non-lesional skin in participants with moderate to severe AD tre…
From ClinicalTrials.gov, last updated 2025-09-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $36,944 in research payments for this study in 2025 (4 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.